S-1: Scilex Faces Going Concern Doubts Amidst Losses and New Crypto Strategy

Scilex Holding Company reports significant net losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern, while also outlining a new, untested cryptocurrency treasury strategy.

Summary

• Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products.
• The company's commercial products include ZTlido (lidocaine topical system) 1.8%, ELYXYB (celecoxib oral solution) for migraine, and GLOPERBA (colchicine USP) oral solution for gout, which launched in June 2024.
• Product candidates in development include SP-102 (SEMDEXA) for sciatica (Phase 3), SP-103 for acute low back pain and chronic neck pain (Phase 2 completed), and SP-104 for fibromyalgia (Phase 1 completed).
• Scilex reported a net loss of $257.8 million for the three months ended September 30, 2025, and $327.9 million for the nine months ended September 30, 2025.
• Net revenue for the three months ended September 30, 2025, was $10.6 million, a decrease of $3.8 million from $14.4 million in the same period of 2024, primarily due to decreased ZTlido sales.
• Net revenue for the nine months ended September 30, 2025, was $25.5 million, a decrease of $16.2 million from $41.7 million in the same period of 2024, mainly driven by a 23% decrease in ZTlido gross sales volume.
• As of September 30, 2025, cash and cash equivalents were approximately $0.9 million, and the accumulated deficit was $888.7 million.
• The company's management has concluded there is substantial doubt about its ability to continue as a going concern for at least one year from the financial statements' issuance date.
• Scilex is registering up to 500,000 shares of common stock issuable upon exercise of Exchange Warrants and up to 1,703,946 shares for resale by selling stockholders, but expects little to no cash proceeds from these offerings due to current stock price being below warrant exercise prices.
• A new cryptocurrency treasury strategy has been adopted, involving the acquisition of Bitcoin, Ethereum, BNB, Doge, and other blockchain-linked cryptocurrencies, which is untested and highly volatile.

Sentiment

Score: 2

Explanation: The company faces severe financial distress with significant and increasing net losses, critically low cash, and an accumulated deficit, leading to substantial doubt about its ability to continue as a going concern. While there are promising product candidates and some positive legal settlements, the financial situation is dire, exacerbated by a new, untested, and highly volatile cryptocurrency treasury strategy. The reliance on future capital raises, with many existing warrants out-of-the-money, adds to the uncertainty.

Positives

• ZTlido, ELYXYB, and GLOPERBA are commercial products, with GLOPERBA launched in June 2024 and ELYXYB approved in Canada in January 2025.
• SEMDEXA (SP-102) has received FDA fast track designation and completed a pivotal Phase 3 study with positive primary and secondary endpoints, with a second Phase 3 study initiated in September 2025.
• SP-103 also received FDA Fast Track status in LBP and completed a Phase 2 trial showing safety, tolerability, and preliminary efficacy in acute LBP.
• The company has a dedicated sales force of over 70 people and established market access for ZTlido, ELYXYB, and GLOPERBA, covering over 200 million lives in the U.S. for ZTlido.
• Legal settlements in Q1 2024 resulted in a $9.4 million gain, and a settlement in Q2 2025 for $0.1 million.
• Unrealized gains on equity investments of $8.3 million and digital assets of $4.7 million were recognized for the nine months ended September 30, 2025.

Negatives

• Scilex incurred significant net losses of $257.8 million for Q3 2025 and $327.9 million for the nine months ended September 30, 2025.
• Cash and cash equivalents are critically low at $0.9 million as of September 30, 2025.
• The company has an accumulated deficit of $888.7 million as of September 30, 2025.
• Net revenue decreased by $3.8 million in Q3 2025 and $16.2 million for the nine months ended September 30, 2025, primarily due to decreased ZTlido sales volume.
• Selling, general, and administrative expenses increased significantly by $159.1 million in Q3 2025, largely due to $140.0 million in issuance costs for reverse recapitalization with Denali and $24.5 million in advisory and financing expenses.
• Loss on derivative liability was $58.4 million in Q3 2025 and $60.3 million for the nine months ended September 30, 2025, driven by changes in stock price and credit risk.
• Change in fair value of debt and liability instruments resulted in losses of $22.0 million in Q3 2025 and $36.5 million for the nine months ended September 30, 2025.
• The Oramed Note and Tranche B Notes impose restrictive operating and financial covenants, and any failure to comply could lead to default.
• Many outstanding warrants are out-of-the-money, making cash exercise unlikely and limiting potential cash proceeds to the company.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and a significant accumulated deficit.
• Heavy dependence on ZTlido sales, as ELYXYB and GLOPERBA are in early commercialization stages, and potential inability to generate sufficient revenue.
• Need for substantial additional funding, which may not be available on acceptable terms or at all, potentially leading to reduced operations or discontinued product development.
• Terms of the Oramed Note and Tranche B Notes restrict operating and financial flexibility; default could accelerate debt repayment and allow creditors to enforce security interests.
• Reliance on sole or single-source suppliers and manufacturers for commercial products and product candidates, posing risks of supply disruption or delays if suppliers fail to comply with regulations or become unavailable.
• Reliance on third parties for clinical trials, with risks of delays, non-compliance, or termination, which could hinder regulatory approval.
• Interim clinical trial data may change, potentially impacting regulatory approval and commercialization.
• ZTlido, GLOPERBA, ELYXYB, and product candidates may have undesirable properties or side effects, leading to regulatory withdrawal, marketing restrictions, or product liability claims.
• Inability to retain key executives could delay development efforts and harm business.
• Disruption in research and development facilities (e.g., natural disasters, cyberattacks) could adversely affect operations.
• Substantial dependence on in-licensed intellectual property for ZTlido and SP-103; termination of agreements could harm commercialization and development.
• Dependence on in-licensed intellectual property for GLOPERBA; loss of license could harm commercialization.
• Inability to maintain patent protection or sufficiently broad patent scope for products and candidates could lead to increased competition.
• Regulatory approval processes are lengthy, unpredictable, and may result in limited indications or post-marketing requirements.
• Failure to comply with health and data protection laws could lead to enforcement actions, penalties, and reputational harm.
• New U.S. administration actions, legislation, and judicial decisions (e.g., overturning Chevron doctrine) could impact business and regulatory environment.
• Market price volatility of common stock due to operational performance, legal disputes, regulatory changes, and overall market conditions.
• Risk of short selling strategies driving down stock price.
• Limitations on using net operating loss and tax credit carryforwards due to ownership changes (Section 382).
• Significant holders may be prohibited from exercising warrants due to beneficial ownership limitations.
• Company may not have sufficient resources to repurchase warrants under certain circumstances.
• Warrants may be exercised on a cashless basis if registration statements are not effective, reducing cash proceeds to the company.
• Untested cryptocurrency treasury strategy exposes the company to high price volatility, potential classification of crypto as securities, and increased regulatory scrutiny.
• Cryptocurrency holdings are less liquid than cash and may not serve as a reliable source of liquidity during market instability.
• Risk of security breaches, cyberattacks, or other compromises to cryptocurrency blockchains leading to loss of assets.
• Counterparty risk if the company generates premium income by selling call options related to cryptocurrencies.

Future Outlook

The company anticipates continued significant expenses for commercialization of existing products and research and development of product candidates. It expects to incur substantial losses for the foreseeable future and may never become profitable. Future funding will depend on equity offerings, debt financings, collaborations, or strategic transactions. A new, untested cryptocurrency treasury strategy has been adopted, with plans to purchase additional Bitcoin, Ethereum, BNB, Doge, and/or other blockchain-linked cryptocurrencies, aiming for appreciation in value, but acknowledging high volatility and potential adverse impacts on financial condition.

Management Comments

• Our guiding principle has always been and remains a patient-first approach, which drives our mission to meet the increasing global demand for more effective and safer non-opioid pain management solutions.
• Through rigorous research and development, we believe we are on the cusp of establishing Scilex as the preeminent name in commercial non-opioid pain management, specifically targeting the unmet needs in both acute and chronic pain sectors with our innovative and leading therapies.
• We believe that we have not only responded to the global demand for safer, more effective pain relief solutions, but also made substantial progress in demonstrating the rapid onset and enhanced safety of our products.
• We believe our currently approved products and future product candidates, if approved by the FDA, could uniquely address what we believe are the significant unmet needs of the targeted populations and become the preferred treatment option for their respective indications.
• We believe developing and commercializing a topical non-opioid product targeting this segment of the pain population represents a commercially attractive strategy.

Industry Context

The company operates in the highly competitive and rapidly advancing biotechnology and pharmaceutical industries, specifically targeting the intense pain management market. It aims to address unmet needs with non-opioid therapies, aligning with a broader trend away from opioid use. The industry faces significant regulatory hurdles, including lengthy FDA approval processes and evolving data requirements. The company's new cryptocurrency treasury strategy places it in a novel and highly uncertain market, subject to significant volatility and an unclear regulatory landscape, contrasting with traditional pharmaceutical investment strategies.

Comparison to Industry Standards

• ZTlido is the first topical delivery system (TDS) product approved by the FDA to demonstrate targeted adhesion performance with a benign dermal safety profile, distinguishing it from many competing lidocaine patches that suffer from poor adhesion.
• ZTlido uses a reduced drug load (36 mg) compared to Lidoderm (700 mg) while achieving bioequivalent lidocaine delivery, suggesting higher efficiency and reduced risk of accidental exposure to residual drug.
• SP-102 (SEMDEXA), if approved, could become the first FDA-approved epidural steroid injection (ESI) for sciatica, addressing a market currently dominated by off-label uses of particulate steroids associated with severe adverse events.
• SP-103 is designed to deliver a lidocaine dose three times higher than any other approved topical lidocaine products, potentially offering greater therapeutic benefit for acute pain.
• SP-104 aims to address the limitations of high-dose commercial naltrexone and inaccurate pharmacy-compounded low-dose formulations for fibromyalgia by offering a novel delayed-release formulation.
• The company's sales force leverages established relationships with target pain specialists, neurologists, and primary care providers, allowing for efficient dual promotion of ELYXYB and ZTlido, and potentially GLOPERBA.

Management Changes

Corporate Governance

Legal Proceedings

• Former Employee Action: Court found in favor of Plaintiffs (Scilex Pharma and Sorrento) against former President Anthony Mack and Virpax Pharmaceuticals, Inc. on most counts. Settlement with Virpax for $6.0 million in cash and future royalties on drug candidates (Epoladerm, Probudur, Envelta). Litigation against Mr. Mack remains ongoing, with a court decision on damages issued July 31, 2025, crediting Mack for Virpax's settlement and assessing costs.
• ZTlido Patent Litigation: Filed against Aveva Drug Delivery Systems, Inc. and Apotex Corp. for infringement of ZTlido patents. U.S. District Court found Aveva's product does not infringe on August 26, 2024. Company is appealing to the U.S. Court of Appeals for the Federal Circuit.
• Former Employees Litigation: Four former employees filed a complaint in California Superior Court for back compensation. Settlement of all claims concluded on June 2, 2025, with confidential terms.

Related Party Transactions

• Sorrento Stock Purchase Agreement: On September 21, 2023, the company repurchased 1,716,245 shares of Common Stock, 29,057,097 shares of Series A Preferred Stock, and warrants from Sorrento for $10.0 million cash, assumption of $101.9 million Oramed Note, credit bid for Junior DIP Facility, and assumption of $12.25 million in legal fees. This resulted in Sorrento no longer holding a majority voting power.
• Oramed Note: Issued a $101.9 million senior secured promissory note to Oramed Pharmaceuticals Inc. on September 21, 2023, with various payment terms, interest rates, and covenants. Oramed's portion of the Tranche B Notes issuance reduced the Oramed Note principal by $22.5 million. Maturity date extended to December 31, 2025, and potentially March 31, 2026.
• Penny Warrants: Issued warrants to Oramed to purchase up to 13,000,000 shares of Common Stock at $0.01 per share. On July 22, 2025, an Option Agreement was entered into with Oramed to repurchase Penny Warrants in two tranches for $27.0 million. Partial exercise occurred on September 30, 2025, repurchasing 3,130,000 Penny Warrants for $13.0 million.
• Tranche B Notes: Issued $50.0 million in senior secured convertible notes to institutional investors and Oramed on October 8, 2024. Oramed's portion involved an exchange and reduction of its Oramed Note principal.
• ZTlido Royalty Purchase Agreement: On October 8, 2024, Scilex Pharma sold the right to receive 8% of net sales of ZTlido Covered Products to ZTlido Royalty Investors and Oramed for $5.0 million. Oramed's portion was paid by exchanging a portion of its Oramed Note principal.
• Gloperba-Elyxyb Royalty Purchase Agreement: On February 28, 2025, Scilex Pharma transferred the right to receive 4% of net sales of Gloperba and Elyxyb Covered Products to institutional investors and Oramed.
• Deferral and Consent under Tranche B Senior Secured Convertible Note: On January 2, 2025, Tranche B Noteholders (including Oramed, Nomis Bay Ltd, BPY Limited, and 3i, LP) agreed to defer amortization payments in exchange for SCLX JV delivering 142,855 shares of Common Stock and a $1.1 million payment.
• ZTlido Rest of World License Agreement: On February 22, 2025, Scilex Pharma entered into a license agreement with RoyaltyVest Ltd. (Licensee) for worldwide (ex-U.S.) rights to ZTlido and SP-103, with each party receiving 50% of net revenue.
• Gloperba Rest of World License Agreement: On February 28, 2025, the company entered into a license agreement with RoyaltyVest Ltd. for worldwide (ex-U.S.) rights to Gloperba, with each party receiving 50% of net revenue.
• Elyxyb Rest of World License Agreement: On February 28, 2025, the company entered into a license agreement with RoyaltyVest Ltd. for worldwide (ex-U.S.) rights to Elyxyb, with each party receiving 50% of Canadian net revenue.
• Semnur Business Combination: On September 22, 2025, the company's majority-owned subsidiary Semnur completed a reverse recapitalization with Denali Capital Acquisition Corp. The company acquired 500,000 Class B ordinary shares of Denali from Denali Capital Global Investments LLC (Sponsor) for $2.0 million cash and 8,571 shares of Common Stock.
• Vivasor Secondary Stock Purchase: On December 5, 2025, the company agreed to buy 6,101,468 shares of Vivasor Holding Company's Series A-1 Preferred Stock from EAR SPV LLC for $9.0 million. Henry Ji, Ph.D., is CEO of Vivasor Holding Company.
• Datavault Investment: On September 25, 2025, the company agreed to purchase 15.0 million shares of Datavault Common Stock and a pre-funded warrant for $150 million in Bitcoin. On September 23, 2025, the company sold 12,500,000 Semnur Common Shares to Biconomy PTE Ltd for $200.0 million in Bitcoin.
• Datavault License Agreement: On November 3, 2025, the company entered into a license agreement with Datavault AI Inc. for exclusive worldwide rights to certain data platform patents and know-how, for a non-refundable license fee of $10.0 million (payable in installments), up to $2.55 billion in net sales milestones, and a 5% royalty on net sales.
• Sale of Datavault Shares: Subsequent to September 30, 2025, the company sold 10,224,112 shares of Datavault for $20.7 million, using $5.7 million to repurchase Bitcoin from Datavault and $15.0 million for working capital.

Stakeholder Impact

• Shareholders: Significant dilution risk from potential future equity offerings and warrant exercises, especially with many warrants out-of-the-money. The reverse stock split may negatively impact market liquidity and overall market capitalization. The new cryptocurrency treasury strategy introduces high volatility and uncertainty to investment value. Anti-takeover provisions may limit opportunities for value realization through corporate transactions.
• Employees: The company's ability to attract and retain qualified personnel is crucial for development efforts, but competition is intense. Employee turnover may occur due to the 'great resignation' trend. Compensation plans, including equity incentives, are designed to attract and retain talent.
• Customers: Continued commercialization of ZTlido, ELYXYB, and GLOPERBA aims to provide effective non-opioid pain management solutions. However, potential supply chain disruptions or product side effects could negatively impact patient access and satisfaction.
• Suppliers/Manufacturers: Reliance on sole or single-source suppliers creates dependency and risk of disruption. Compliance with FDA regulations by third-party manufacturers is critical for product authorization.
• Creditors: The company's substantial debt obligations (Oramed Note, Tranche B Notes) and negative working capital pose significant risks. Covenants in debt agreements restrict financial and operational flexibility, and default could lead to accelerated repayment and enforcement of security interests.

Next Steps

• Continue commercialization efforts for ZTlido, GLOPERBA, and ELYXYB.
• Advance development of product candidates: SP-102 (SEMDEXA), SP-103, and SP-104, including initiating a second Phase 3 study for SP-102.
• Expand digital marketing efforts to broaden awareness of commercial products.
• Negotiate additional payor contracts for market access.
• Support investigator-initiated research studies for ZTlido in new indications.
• Identify and certify new suppliers for sodium hyaluronate for SP-102.
• Explore and evaluate additional acquisition or in-licensing opportunities for non-opioid assets.
• Seek additional financing through equity offerings, debt financings, collaborations, government contracts, or other strategic transactions.
• Implement and execute the new cryptocurrency treasury strategy, including purchasing additional blockchain-linked cryptocurrencies.
• Continue to analyze SP-103 Phase 2 trial data and investigator study results for ZTlido in chronic neck pain.
• Plan for an Investigational New Drug (IND) application with the FDA for SP-104 to enable further clinical development and initiation of a planned multi-center placebo-controlled registration trial.
• Pay remaining $1.7 million to Tumim Stone Capital, LLC by December 15, 2025, to terminate the equity line of credit agreement.
• Make the second installment of the Option Payment Amount to Oramed by December 16, 2025, to maintain the option to repurchase Penny Warrants.
• Make monthly installment payments for the Sponsor Note, FutureTech Note, and Denali Underwriter Notes, starting October 1, 2025.

Key Dates

Recommendation

The company's financial position is extremely precarious, marked by substantial and escalating net losses, critically low cash reserves, and an accumulated deficit of nearly $900 million, leading management to express 'substantial doubt about its ability to continue as a going concern.' While the company has a pipeline of non-opioid pain management products, their commercial success is insufficient to offset the massive cash burn. The new, untested cryptocurrency treasury strategy introduces an additional layer of extreme volatility and regulatory uncertainty, which is highly speculative and could further destabilize the company's financial health. The reliance on future capital raises, with many existing warrants out-of-the-money, suggests significant dilution for current shareholders is likely, or the company may fail to secure necessary funding. The combination of severe financial distress, operational risks, and a highly speculative new business direction makes this a high-risk investment with a strong likelihood of further value erosion.

Keywords

Non-opioid pain management, Biopharmaceutical, SEC filing, S-1, ZTlido, ELYXYB, GLOPERBA, SEMDEXA, SP-103, SP-104, Clinical trials, FDA approval, Warrants, Equity offering, Debt financing, Going concern, Net loss, Accumulated deficit, Cryptocurrency, Bitcoin, Blockchain, Intellectual property, Patent litigation, Regulatory risk, Nasdaq listing, Reverse stock split